Metallocenes as Target Specific Drugs for Cancer Treatment.

Abstract

The application use of organometallic compounds into the cancer research was established in the late 1970s by Köpf-Maeir and Köpf. This new research area has been developed for the past thirty years. In the early 1980s, Jaouen and coworkers recognized the potential application of organometallic compounds vectorized with pendant groups that can deliver the drug to certain specific receptors. This is what is called nowdays Target Specific Drugs. This review will focus on metallocenes vectorized with steroids derivatives of hormones, nonsteroidal and selective endrocrine modulator.

• Authors: Enrique Meléndez
• Journal: Inorganica chimica acta (Inorganica Chim Acta) Vol. 393 Pg. 36-52 (Dec 01 2012) ISSN: 0020-1693 [Print] Switzerland
• PMID: 23180884 (Publication Type: Journal Article)